• Supportive and symptomatic care females issues

• Laboratory diagnosis of Gaucher disease GD type1

• Patient-reported outcome measures for patients with Gaucher disease

• Symptomatic care of children with non-neuronopathic Gaucher disease

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1

Dardis, A., Michelakakis, H., Rozenfeld, P. et al. Orphanet J Rare Dis 17, 442 (2022).

 

Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease.

Biegstraaten M, Cox TM, Belmatoug N, et al. Blood Cells Mol Dis. 2018;68:203-208.

 

Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher disease.

Hollak CE, Aerts JM, Belmatoug N, et al. Blood Cells Mol Dis. 2010;44(2):86-7.

 

Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease.

Hollak CE1, vom Dahl S, Aerts JM, et al. Blood Cells Mol Dis. 2010;44(1):41-7.

 

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement.

Cox TM, Aerts JM, Andria G, et al. J Inherit Metab Dis. 2003;26(6):513-26.

 

Management of neuronopathic Gaucher disease: a European consensus.

Vellodi A, Bembi B, de Villemeur et al. J Inherit Metab Dis. 2001 Jun;24(3):319-27.

EWGGD Code of Practice with Industry

EWGGD Working Group Policy

EWGGD Statement on Home Therapy